Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 26NIH 17INDUSTRY 13NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Specimen Handling 47Magnetic Resonance Spectroscopy 38Cyclophosphamide 28Vincristine 22Radiation 19Dexamethasone 19Etoposide 18Cisplatin 18Carboplatin 17Biopsy 17Radiotherapy 16Doxorubicin 13Cytarabine 13daratumumab 12Leucovorin 12Methotrexate 11Gemcitabine 11X-Rays 10Standard of Care 10Platinum 10Docetaxel 10durvalumab 9Rituximab 9Radiotherapy, Intensity-Modulated 9Prednisone 9Practice Guidelines as Topic 9Calcium Dobesilate 91,2-diaminocyclohexaneplatinum II citrate 9merphos 8dexamethasone acetate 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × ibrutinib × 90 days × Clear all
NCT02436707 2026-04-20

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase 2 Active not recruiting
129 enrolled
Lymphoid

Lymphoma

NCT05998642 2026-04-14

Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

Canadian Cancer Trials Group

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡